MSK Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
:Co-chairs: Thomas M. Link, MD | :Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD | ||
:RSNA Staff Support: Susan Stanfa | :RSNA Staff Support: Susan Stanfa | ||
* [ | * [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster] | ||
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | ||
Revision as of 17:08, 30 July 2020
- Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
- RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Working Documents
- QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease